当前位置: 首页 > 期刊 > 《中国当代医药》 > 2018年第12期
编号:13229570
基于CRISPR—Cas9定向编辑CCL17和CCL22基因的研究(5)
http://www.100md.com 2018年4月25日 《中国当代医药》 2018年第12期
     [19]Kang S,Xie J,Ma S,et al.Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets[J].Immunobiology,2010,215(2):153-162.

    [20]Curiel TJ,Coukos G,Zou L,et al.Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival[J].Nat Med,2004,10(9):942-949.

    [21]Tani K,Azuma M,Nakazaki Y,et al.Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage Ⅳ renal cell cancer in Japan:clinical and immunological findings[J].Mol Ther,2004,10(4):799-816.

    [22]Christian M,Cermak T,Doyle EL,et al.Targeting DNA double-strand breaks with TAL effector nucleases[J].Genetics,2010,186(2):757-761.

    [23]Bibikova M,Beumer K,Trautman JK,et al.Enhancing gene targeting with designed zinc finger nucleases[J].Science,2003,300(5620):764-764.

    [24]Cho SW,Kim S,Kim JM,et al.Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease[J].Nat Biotechnol,2013,31(3):230-232.

    [25]Li J,Shou J,Guo Y,et al.Efficient inversions and duplications of mammalian regulatory DNA elements and gene clusters by CRISPR/Cas 9[J].J Mol Cell Biol,2015,7(4):284-287.

    (收稿日期:2018-01-30 本文編辑:祁海文), 百拇医药(高淑慧 瞿创 吴凤麟 沈晗)
上一页1 2 3 4 5